Navigation Links
Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:10/30/2008

LONDON and NEW YORK, Oct. 30 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on first-in-class novel, non-steroidal anti-inflammatory drugs, announced today that Dr. Yuval Cohen, President of Morria, will deliver a presentation at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, Nov. 10 from 10:45 to 11:10 a.m. in the Louis room (4th Floor) at The New York Palace Hotel.

Dr. Cohen's presentation will provide an overview of Morria's development of its leading clinical programs in allergic rhinitis (hay fever) and skin inflammation (contact dermatitis), as well as its pre-clinical progress in asthma, inflammatory bowel disease, ophthalmology and cystic fibrosis. The presentation will include a review of the clinical results reported from Morria's recently completed Phase II double blind placebo controlled study in 105 patients suffering from allergic rhinitis, a study that also included a steroid comparator.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focusing on the development of novel, anti-inflammatory pharmaceuticals termed Multi-Functional Anti-Inflammatory Drugs (MFAID). Morria is determined to become a pivotal player in the anti-inflammatory drug market through the introduction of novel drugs for the treatment of a variety of acute and chronic inflammatory conditions including respiratory, skin, airway and gastro-intestinal inflammatory diseases. For more information please visit http://www.morria.com.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information.

Richard Lewis Communications, Inc.

212-827-0020

Cecelia Heer - Investors

cheer@rlcinc.com

Tim Rathschmidt - Media

trathschmidt@rlcinc.com


'/>"/>
SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
2. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
3. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
4. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
5. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
6. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
9. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
10. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
11. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
Breaking Biology Technology:
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
Breaking Biology News(10 mins):